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Introduction:

Ménétrier disease

Ménétrier disease is a rare, acquired disease characterized by enlarged
gastric folds in the fundus and body with foveolar hyperplasia, cystic
dilation of gastric glands , reduced numbers of parietal and chief cells
with hypochlorhydria and protein losing enteropathy. We present a case
of HIV as a new perpetrator for Ménétrier disease causing protein losing
enteropathy.
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Prevalence:

Very rare with fewer that 400 cases worldwide

Clinical Manifestations:

- E
 pigastric pain - 65 percent
- Weight loss - 45 percent
- Asthenia - 60 percent
- E
 dema - 38 percent
- Anorexia - 45 percent										 - Vomiting - 38 percent

Case Presentation

Diagnosis:

Chief Complaint:

A 41-year-old hispanic male with AIDS, chronic hepatitis C, and a history of ascending colitis
with cecal ulcer, presented with 3-month history of unintentional weight loss of 20 pounds and
diffuse pain in epigastrium and RUQ, with associated diarrhea, nausea, and vomiting.
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Figure 3

Pertinent positives: Tenderness in epigastrium, and ascites with anasarca.

Our Hypothesis

Investigations:

Laboratory data: Severe hypoalbuminemia (2.0gm/dL), hyponatremia (127 meq/dL), peripheral
eosinophilia- 25%.
Ascitic fluid analysis: SAAG of <1.1.

HIV

Ménétrier’s

Discussion:

Overexpression of transforming growth factor alpha has been proposed to play a role in the
pathophysiology of Ménétrier’s disease. Its levels are increased in the gastric mucosa of
patients with Ménétrier’s disease. TGF-alpha is responsible for maintaining gastric homeostasis
by inhibiting acid secretion while increasing gastric mucous production. HIV-1 tat gene product
stimulates TGF-alpha production, which activates the EGF receptor. Our hypothesis states
that overexpression of TGF-alpha by HIV can lead to gastric epithelial changes consistent with
Ménétrier’s disease via the pathway shown (Fig. 4).

•	Octreotide has been shown to improve enteral protein loss. No clear data or study is available
for duration of treatment.
•	Case reports for treatment with a monoclonal antibody directed against the epidermal growth
factor receptor (Erbitux).
• Surgical option with total gastrectomy.

Prognosis:

The natural history of Ménétrier’s disease is not well characterized. Scattered reports have
demonstrated the evolution from Menetrier’s disease to gastric atrophy over four to eight
years, with return of the serum albumin concentration to normal The risk of gastric cancer in
patients with Ménétrier’s disease is uncertain, Other reports indicate that sepsis, vascular and/
or thromboembolic complications may be a greater threat to patients with Menetrier’s disease
than malignant transformation.

Key Points:

Treatment:
Prednisone 40 mg + Octreotide 0.1 mg SQ BID for 5 days followed by monthly intramuscular
injection.
Albendazole 400 mg for 3 days for possibility of Ancylostoma caninum (empiric).

•	Gross: Striking enlargement of gastric folds or rugae, confined to the body and fundus.
•	Histology: Extreme foveolar hyperplasia with glandular atrophy on a full thickness biopsy (or
endoscopic snare or suction biopsy).

Treatment:

Physical Examination:

Initial esophagogastroduodenoscopy (EGD) with superficial gastric biopsy: Findings consistent
with eosinophilic gastritis.
Stool studies: Occasional Charcot-leyden crystals, ova and parasites negative.
CMV DNA: Negative.
Repeat EGD: Enlarged gastric fold in fundus and cardia with diffusely erythematous, nodular
and friable mucosa.
Endoscopic ultrasound with full thickness gastric snare biopsy: Foveolar hyperplasia with
superficial erosions associated with acute on chronic inflammation and sparse fundic glands
with reactive changes (Fig. 1& 2).

(Other names include Hypoalbuminemic hyperplastic gastropathy
and hyperplastic hypersecretory gastropathy)

•	Ménétrier disease is a rare cause of gastric rugal hypertrophy with protein losing enteropathy
likely caused by elevated levels of transforming growth factor-alpha (TGF-α).
•	AIDS patients may have higher risk of Ménétrier disease due to HIV-1 tat gene related over
production of TGF-α.
•	Ménétrier disease should be considered in an AIDS patient with abdominal pain and protein
losing enteropathy who has no evidence of gastrointestinal CMV or H. pylori infection.

Figure 4. HIV induced upregulation of TGF-alpha, leading to Ménétrier disease. TGF: Tumor growth
factor, PDX-1: Pancreatic and duodenal homeobox 1.

